Introduction
Pathologic cardiac hypertrophy is a chronic condition characterized by increased ventricular mass in response to an increased load in the presence of hypertension, aortic stenosis, heart valve defects, or myocardial infarction (Mill et al., 2011) . Cardiac muscle hypertrophy can provide a short term beneficial compensatory response by reducing diastolic wall stress and increasing developed force, but, at subsequent stages of cardiac remodeling, hypertrophy culminates in contractile failure and ventricular dilatation (Frey and Olson, 2003; Gardin and Lauer, 2004) and is associated with increased morbidity and mortality (Levy et al., 1990) .
The hypertrophic muscle mass develops disproportionally to neovascularization, a mismatch that results in tissue hypoxia and contributes to the transition to heart failure (Izumiya et al., 2006; Shiojima et al., 2005) . Hypoxia signals mediators that can satisfy the demand for increased capillary density. For example, activation of the transcription factor HIF-1α (hypoxia-inducible factor-1α) is known to induce expression of vascular endothelial growth factor (VEGF) and thus promote neovascularization (Carmeliet, 2000; Forsythe et al., 1996; Tirziu and Simons, 2005) . However, muscle mass can accumulate faster than HIF-1α and VEGF can stimulate angiogenesis, resulting in continued hypoxia, a cellular stress that induces the accumulation of p53 (Das et al., 2010; Ravi et al., 2000; Sano et al., 2007) .
The p53 protein is a potent transcription factor (Beckerman and Prives, 2010) and has been the subject of several studies related to biomechanical stress and cardiac hypertrophy (Leri et al., 1998 (Leri et al., , 2000 Tsukamoto et al., 2006) . Under hypoxic conditions, increased p53 protein levels and activity were noted in heart cells (Das et al., 2010; Long et al., 1997) . The increase in p53 was associated with inactivation of HIF-1α and reduction in VEGF expression (Ravi et al., 2000; Sano et al., 2007) . PUMA, a transcriptional target of p53 and Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/yviro activator of apoptosis, is also an important mediator of cell death in the transition to heart failure (Mandl et al., 2011) . Thus the p53 pathway plays a central role in down-regulating VEGF expression and promoting cardiac cell death.
The mammalian VEGF family consists of the variants VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor. All forms of VEGF are secreted and may differ in binding affinity with one, two or all three VEGF receptors. Splice variants of VEGF-A yield a variety of isoforms, though VEGF-A 165 has been studied extensively (Giacca and Zacchigna, 2012) . Experimental studies have shown that VEGF-A 165 (referred to here as VEGF-A) is an essential endothelial mitogenic agent in angiogenesis and vasculogenesis (Pettersson et al., 2000) , induces mitosis of adult cardiomyocytes (Laguens et al., 2002) and is also associated with the recruitment and activation of resident cardiac stem cells to repair sites of ischemic tissue (Ferrarini et al., 2006; Vera Janavel et al., 2006) . Administration of recombinant VEGF-A has shown therapeutic benefit in animal models of cardiac hypertrophy induced by transaortic coarctation (Friehs et al., 2006) , though the administration of recombinant protein may prove to be inefficient for prolonged treatments.
Gene therapy is a promising alternative to the application of recombinant VEGF. The use of viral vectors that efficiently transduce cardiac cells in vivo can provide localized concentrations of VEGF, thus increasing the effect of the transgene (Giacca and Zacchigna, 2012) . In addition, gene therapy may provide an opportunity for preemptive treatment, especially in the case that the gene transfer vector provides on-demand expression of VEGF. Controlled expression of VEGF is critical to avoid undesired effects such as hemangioma formation (Lee et al., 2000; Schwarz et al., 2000) . To this end, our laboratory has developed several gene transfer vectors where expression of the transgene is controlled by p53 acting upon a synthetic p53-responsive promoter, termed PG. We have shown that these retroviral, adenoviral and adenoassociated virus vectors offer high-level expression only in the presence of active p53 (Bajgelman et al., 2013; Bajgelman and Strauss, 2008; Merkel et al., 2010; Strauss and Costanzi-Strauss, 2004 ). However, the use of adeno-associated virus (AAV) may be especially well suited for cardiac gene transfer since these vectors combine the advantages of low immune response against transduced cells and the possibility of long term expressions of the therapeutic gene (Bennett, 2003; Raake et al., 2008) .
Here we propose a new therapeutic strategy to prevent the deterioration of cardiac function associated with hypertrophy. For this, we employed our adeno-associated vector which expresses the human VEGF-A cDNA driven by a chimeric promoter responsive to p53 (Bajgelman et al., 2013) . In theory, as p53 levels increase during the transition to decompensated cardiac hypertrophy, the p53-responsive AAV vector should provide expression of VEGF-A. In this way, the negative role of p53 in response to physiologic stress is counterbalanced by using p53 to drive on-demand VEGF-A transgene expression which, in turn, should contribute to neovascularization and preservation of cardiac function.
Results

AAVPG-VIG provides p53-responsive expression of VEGF in transduced primary cells
The AAVPG-VIG vector encodes the human VEGF-A 165 (VEGF-A) cDNA driven by the chimeric p53 responsive promoter, PGTxβ (Bajgelman et al., 2013; Bajgelman and Strauss, 2008) . In order to verify the functionality of the vector in primary cardiac cells, cardiomyocytes isolated from neonatal rat heart were transduced with the AAVPG-VIG vector and subjected to increasing concentrations of doxorubicin, an anthracycline known to induce transactivation by p53, yielding significant amounts of secreted human VEGF-A, as measured in the cell culture medium by ELISA ( Fig. 1A) . In Fig. 1B , we demonstrate that a similar response also occurs using AAVPG-luc virus, encoding the luciferase reporter gene. The fall in transgene expression at the highest drug dose may have been due to toxicity, but this appears not to have altered vector expression since the result is consistent even in the absence of normalization (Fig. S1 ). These assays show that a treatment known to activate p53 results in the induction of expression from AAVPG vectors in a comparable manner.
We have directly tested whether the co-transduction of the AAVPG and AAVCMV vectors is associated with any cross talk between the vectors. As seen in Fig. S2 , the performance of AAVPG-luc was the same whether or not AAVCMV-LacZ was present. Therefore, the co-transduction approach yields a reliable internal control.
In vivo cardiac transduction using viral vectors expressing the LacZ reporter gene
We performed in vivo cardiac transduction followed by observation of β-galactosidase (LacZ) expression driven by the constitutive CMV promoter. Wistar rats were injected in the left ventricle using either 10 8 genome copies (GC) AAVCMV-LacZ (serotype 2) or 10 8 Fig. 1 . Expression of AAVPG viruses can be induced in cardiomyocytes isolated from neonatal rat heart. (A) Cells were co-transduced with an equimolar mixture of the adeno-associated vectors AAVPG-VIG and AAVCMV-LacZ. After 24 h, medium was changed and cells were subjected to the indicated concentrations of doxorubicin. Human VEGF-A expression was quantified in the supernatant by ELISA, and normalized by β-gal activity presented by the cellular lysates. The condition without doxorubicin was called 1. (B) Cells were co-transduced with an equimolar mix of the adeno-associated vectors AAVPG-luc and AAVCMV-LacZ. After 24 h, medium was changed and cells were subjected to the indicated concentrations of doxorubicin. The cells were harvested and luciferase (Luc) activity was quantified. β-gal was used to normalize Luc activity. The condition without doxorubicin was called 1. n Po 0.05 and nn Po 0.01 vs. control. One-way ANOVA followed by Bonferroni posthoc test. Mean þSEM, n¼ 3.
Infectious Units (IU) of Adenovirus-CMV-LacZ (serotype 5). The animals were euthanized after 4 weeks, hearts were removed, processed and stained with X-Gal to verify the transduction efficiency. Though both vectors resulted in cell marking, the AAV2 vector was qualitatively superior to Ad5 (Fig. S3 ). This result is critical in confirming that transduction of rat heart with AAV serotype 2 was reliable. The use of other serotypes, such as 6 or 9, is known to yield higher rates of transduction (Asokan et al., 2012) , yet, as we will show, serotype 2 was adequate for our proofof-concept studies.
Transaortic constriction (TAC) is associated with activation of a p53 target gene and increased arterial systolic pressure In order to evaluate the effect of stenosis on the activity of p53, surgery including TAC or not (Sham) was performed. Data from echocardiography showed no alteration with cardiac function comparing TAC and Sham groups. As expected, animals submitted to TAC displayed higher blood pressure ( Fig. 2A ). In this pilot assay, animals were euthanized one week after TAC, total RNA collected and expression of p21, a transcriptional target of p53, was examined by qPCR. As seen in Fig. 2B , p21 levels were increased in the TAC group. In this way, the expected rise in blood pressure after TAC was also correlated with alteration in expression of a p53 target gene.
In vivo evaluation of the AAVPG-VIG vector: echocardiography suggests a tendency to cardiac dysfunction in the TAC þLUC group
We conducted an in vivo test where animals underwent surgery including TAC or Sham operation and transduction with the therapeutic vector, AAVPG-VIG (VIG), or a control vector, AAVPG-Luc (LUC). The four experimental groups are referred to as (i) Sham þLUC, (ii) Sham þVIG, (iii) TAC þLUC, and (iv) TAC þ VIG. Animals were examined by echocardiography at 4, 6, 8 and 12 weeks after the TAC (or Sham) procedure, yet alterations were noted only at the final time point, in agreement with the literature (Litwin et al., 1995) . At the end of this period, careful direct hemodynamic study was performed.
Even after 12 weeks of follow-up, we observed only a slight decrease in cardiac function, as measured by parameters such as ejection fraction (EF) and fractional shortening (FS), in LUC þTAC animals. Such a modest response to TAC is not without precedent (Smeets et al., 2008) . However, the VIG þ TAC group showed a tendency to maintain proper function ( Fig. 3A and B ). Since the alterations were not statistically significant, we used a more sensitive assay that does not rely simply on base line functional levels. To this end, the assessment of cardiac work under conditions of hemodynamic stress was used to reveal functional changes more clearly (dos Santos et al., 2010a) .
Therapeutic benefit of AAVPG-VIG treatment revealed upon induction of sudden hemodynamic stresses
In agreement with the literature (dos Santos et al., 2010a; Fletcher et al., 1982; Kumar et al., 1970) , functional parameters assessed by direct catheterization did not show significant differences between our four experimental groups (Table S1 ). Using the protocol previously described by dos Santos et al. (2010a) , the animals from the four experimental groups were subjected to sudden pressure or volume alterations in order to induce hemodynamic stress.
The induction of afterload stress, as expected, led to an increase in systolic arterial pressure (50-70%) over the basal values for all experimental groups (see Supplemental Fig. S4 ). Preload stresses did not produce significant changes on basal values. As seen in Fig. 3C and D, the combination of the different hemodynamic stresses induced significant reduction in parameters of cardiac function, such as stroke volume and stroke work generation, in all groups. Interestingly, while Sham groups exhibited slight reductions on stroke volume associated with increased recruitment of stroke work under hemodynamic stresses, TACþ LUC animals have a dramatic decrease in ejected volume ( Fig. 3C ) with a clear reduction on stroke work generation ( Fig. 3D ). Conversely, it was observed that the stroke volume of TACþVIG group in response to the stress protocols was equivalent to the Sham group, with significant recruitment of stroke work. Hence the induction of hemodynamic stress revealed functional differences due to the TAC and gene therapy procedures. In this experiment, the gene therapy approach of providing the AAVPG-VIG vector was shown to be effective in preserving cardiac function. Biometry and histomorphometry reveal that AAVPG-VIG treatment preserved cardiac function, though it did not prevent hypertrophy
We analyzed the water content in the lungs to assess pulmonary congestion as an index of cardiac decompensation. Although only TACþLUC animals exhibited a tendency for increased lung water content when compared to SHAMþLUC, with normal levels in TACþVIG, a statistically significant difference between TACþLUC and TACþVIG was not reached (Fig. S5 ).
The ratio of heart/body mass in the TAC groups was significantly increased when compared to Sham (Fig. 4A ). Histological analysis on the remodeled myocardium showed a significant increase in the estimated volume of myocyte nuclei in the hearts subjected to TAC, a parameter which was not significantly influenced by VIG injection (Fig. 4B ). These morphologic indicators of hypertrophy, ratio of heart/body mass and volume of myocyte nuclei, were not altered by AAVPG-VIG treatment, yet functional parameters were preserved, as shown above.
Consistent with the notion that myocardial fibrosis is associated with loss of function, we observed that the interstitial collagen content was significantly increased only in the animals treated with TAC þ LUC (Fig. 4C) , the same group that showed Fig. 3 . Therapeutic virus enhanced cardiac function. (A) Echocardiography revealed a tendency for reduced ejection fraction in the TAC þLUC group. The TAC þVIG group, which received therapeutic virus, showed a tendency to preserve cardiac function; however, this observation was not statistically significant. Gray line represents normal range for non-operated rats. (B) Echocardiography revealed a tendency to reduce fractional shortening in the TAC þ LUC group; however this observation was not statistically significant. The TACþ VIG group, which received the therapeutic virus, was associated with preserved cardiac function. Gray line represents normal range for non-operated rats. Effects of hemodynamic stress protocols on ejected stroke volume (C) and work generation (D) of all experimental groups. AS, afterload stress; MPS, mild preload stress; SPS, severe preload stress. n P o0.05 vs. all groups; # Po 0.05 vs. TACþ LUC. Two-way ANOVA followed by Bonferroni posthoc. Mean þSEM, SHAM þLUC: n¼ 3, SHAMþ VIG: n¼ 5, TAC þ LUC: n¼ 4, and TAC þVIG: n¼ 4. severe loss of function upon hemodynamic stress ( Fig. 3C and D) . In contrast, the collagen content in the hearts from the TAC þVIG group was not different from the Sham groups, indicating that the lack of fibrosis was correlated with the preservation of cardiac function by AAVPG-VIG treatment (Fig. 4C ).
Finally, we evaluated the capillary density in the myocardium from all experimental groups. As shown in Figs. 4D and S6, while TAC þLUC exhibited low capillary density when compared to Sham groups, the therapy with AAVPG-VIG was able to counteract this pathological change, preventing the capillary rarefaction that often accompanies myocardial stress and hypertrophy. Since AAVPG-VIG was shown to offer p53-responsive expression of VEGF-A in our in vitro assays, we postulate that a similar mechanism was responsible for regulating virus expression, and consequently preserving capillary density, in vivo.
Discussion
The results of the present study provide practical evidence of the functionality of a new therapeutic strategy to prevent deterioration of cardiac function associated with hypertrophy. Since pathological hypertrophy is associated with reduced capillary density, the cardiac tissue can become hypoxic. The natural response is to induce HIF-1α which, in turn, promotes the expression of VEGF. Over time, this mechanism may prove insufficient and tissues may suffer enough stress that p53 becomes activated. Among its many functions, p53 can inhibit HIF-1α and bring about the loss of VEGF expression, thus promoting the further deterioration of cardiac tissue and function. To bypass this mechanism, we developed a vector derived from adeno-associated virus, which contains the human VEGF-A 165 cDNA driven by a chimeric promoter responsive to p53, called PG. In this scenario, the activation of p53 would induce VEGF expression and, therefore, promote angiogenesis. The assays performed here indicate that treatment with the AAVPG-VEGF vector can preserve cardiac function even though it does not prevent the development of hypertrophy itself.
The function of p53, the notorious tumor suppressor gene, did not gain its fame based on its association with cardiopathies. However, the fundamental role of p53 is to coordinate growth arrest or death of cells that have suffered physiologic stress, such as hypoxia. Many of the lessons of p53 activity learned in cancer models may have application in the treatment of conditions such as cardiac hypertrophy. The role of p53 in cardiovascular disease may be underexplored, but its importance has been brought to light.
Our prior work has focused on the development of viral gene therapy vectors where transgene expression is controlled by p53. As part of this work, we have previously described the construction of a chimeric p53-responsive promoter (PGTxβ, or simply PG) and reporter assays that demonstrate robust expression in a controlled manner, dependent on the activity of p53 (Bajgelman and Strauss, 2008) and have explored the use of such vectors in cancer models (Merkel et al., 2010; Strauss et al., 2005; Strauss and Costanzi-Strauss, 2004) . In a separate study using the AAVPG vector, we have clearly shown its p53-responsiveness, including when cells treated with doxorubicin, hypoxia or mechanical stress (Bajgelman et al., 2013) . We hypothesized that the application of the AAVPG vector would be appropriate for cardiac hypertrophy since, according to the literature, the accumulation of p53 occurs in a transition phase, before the deterioration of cardiac function from a compensated to a non-compensated state (Das et al., 2010; Sano et al., 2007) . Hence, the p53-responsive mechanism should provide virus expression during a critical phase of hypertrophy.
The properties of VEGF extend beyond the induction of angiogenesis. It has been shown that intracardiac injection of VEGF improves heart performance and inhibits cardiomyocyte apoptosis (Ruixing et al., 2007) , induces the mitosis of adult cardiomyocytes (Laguens et al., 2002) , induces hyperplasia of cardiomyocytes (Laguens et al., 2004) and it has been suggested that it also participates in the mobilization of stem cells for cardiac tissue repair (Ferrarini et al., 2006) . Our observations are consistent with these reports since our experimental results in animals that underwent TAC and received the therapeutic AAVPG-VIG virus were associated with preservation of cardiac function that was correlated with preservation of capillary density and the lack of fibrosis, yet animals that did not receive gene therapy suffered loss of function, capillary rarefaction and induction of fibrosis.
The morphologic signs of hypertrophy upon TAC, such as increased heart/body weight ratio and nuclear volume, persisted even though cardiac function was preserved with AAVPG-VIG treatment. The heart/body weight ratio did reveal a statistically significant increase with TAC, though we point out that body weight was not altered and that peripheral edema was not observed, contributing to the reliability of the observed ratio. Moreover, our morphologic observations were well substantiated by the histologic evaluation and both methods point to the appearance of hypertrophy in the TAC groups.
Further studies are required, but the preservation of function appears to be related to the maintenance of capillary density and reduction of collagen deposition. At this time we can only speculate as to whether the capillaries were indeed preserved or if they represent neovascularization. The latter scenario does seem likely since heart mass was increased without loss of capillary density, suggesting that new vessels were formed during the remodeling process. Our attempts to quantify neovascularization were met with technical difficulties, but we did count vessels upon staining with PAS. Even so, the functional result supports the notion that treatment with AAVPG-VIG preserved cardiac performance.
The TAC procedure did not yield profound alterations in ejection fraction or fractional shortening when measured at base line (in the absence of additional hemodynamic stress). This result is not without precedent as it has been observed in several animal models (Smeets et al., 2008) . Moreover, the concept of cardiac reserve, the heart's ability to perform beyond its basal level, supports the notion that the impact of TAC may not be seen without added stress (dos Santos et al., 2010a) . We do not rule out the possibility that a longer follow-up period may have revealed base line alterations due to our TAC procedure. Alternatively, a more acute model, such as induction of infarct, may be used in future studies in order to reveal pronounced changes in heart function. In the present study, the benefit of the AAVPG-VIG vector was revealed when sudden hemodynamic stress was applied. This method is sufficiently sensitive such that changes in cardiac function are revealed even in animals that had no visible changes under basal conditions (dos Santos et al., 2010a) . Such an approach supports analysis of heart function at stages that precede obvious deterioration and it has been used to assess strategies to prevent cardiac deterioration post-myocardial infarction using transplantation of fibroblast cells genetically modified to express VEGF or adult stem cells of different origins (Danoviz et al., 2010; dos Santos et al., 2010b; Goncalves et al., 2010; Nakamuta et al., 2009 ).
The outflow constriction by aortic coarctation is clearly a model of cardiac hypertrophy rather than of heart failure. In addition, it is already consensual that this model does not mimic the most common clinical condition of cardiac hypertrophy related to essential hypertension, mainly because we cannot be sure that the dynamics of the hypertrophy process after an acute pressure overload is equivalent to that observed gradually in hypertensive humans. Notwithstanding, this model has been intensively used during the last two decades as a rat model for pathophysiological and therapeutic investigations, since the partial aortic constriction has low mortality during surgery and rapidly leads to cardiac remodeling including hypertrophy, fibrosis, apoptosis and capillary rarefaction, accompanied by late evidences of heart failure such as afterload mismatch, reduced ejection fraction and lung congestion seen here 12 weeks after TAC.
The in vivo transduction efficiency seemed to be sufficient to bring about the desired functional result. Since we used a relatively low titer AAV2 as compared to examples from the literature (Aikawa et al., 2002; Kimura et al., 2001; Raake et al., 2008; Su et al., 2004) , the transduction level may have been suboptimal, though this was not tested directly. Even though the use of serotypes 6 and 9 would be more appropriate in a cardiac model (Asokan et al., 2012) , the functional benefit of our AAV2 vector was clearly evident. The use of AAV6 or 9 may facilitate intravenous administration of the vector, yet the functional results of this proof-of-concept study indicate that we encountered no shortcoming with the intramuscular delivery of AAV2.
AAV vectors have several features that make them especially appropriate for gene therapy in the cardiovascular system in general and applicable to hypertrophy in particular. These vectors are quite stable and provide long-term expression of the transgene, yet do not, for the most part, integrate in the genome of the host cells. AAV vectors are also much less likely to provoke an immune response than an adenoviral vector (Bennett, 2003; Li et al., 2007) . These features, as well as the p53-responsive transcriptional control, contribute to the vigilant aspect of the AAVPG-VIG vector. As was performed here, the AAVPG-VIG vector can be administered before hypertrophy has taken hold with the expectation that expression of the therapeutic gene be induced as needed. Such 'on demand' expression of VEGF should lessen the likelihood of hemangioma formation (Lee et al., 2000; Schwarz et al., 2000) .
The strategy presented here will require additional refinements before consideration for clinical application. For example, the AAVPG-VIG vector expresses the transgene when p53 is activated, but is not specific for cardiac cells. In order to improve safety, additional mechanisms may be incorporated to ensure that the vector expresses only in heart cells in addition to the conditional expression regulated by p53. As mentioned above, the AAV vector can also be improved by changing the viral capsid in order to direct tissue tropism according to the viral serotype (Asokan et al., 2012; Palomeque et al., 2007) , thus enhancing transductional specificity of cardiac cells.
We hypothesize that this gene therapy approach may be especially well suited to the preservation of cardiac function while other treatments are sought to relieve the underlying cause of pressure overload such as in chronic hypertensive patients. In other words, this pre-emptive strategy may be suited to preserve cardiac function even if hypertrophy is not fully reversed or prevented. In fact, we believe that this strategy could be very useful since it can potentially modulate the pathological process in an 'on demand' manner depending on the injury degree and the phase of the disease, especially considering that the vector used here could induce expression of the transgene (such as therapeutic VEGF) with a damage-responsive promoter (such as PG, used in this study).
We conclude that the new AAV viral vector encoding the VEGF-A cDNA driven by the chimeric promoter responsive to p53 combines the advantages of low immunogenicity, high transduction efficiency, robust and controlled expression which is induced on demand by hypertrophic cells and may be used for the development of new therapeutic approaches to preserve cardiac function associated with cardiac hypertrophy.
Material and methods
Cell culture and lines
The adenovirus-transformed, human embryo kidney cell line 293T was maintained in DMEM (Life Technologies, USA) supplemented with 10% FBS (HyClone, USA), 100 mg/mL gentamycin, 50 mg/mL ampicillin, and 2.5 mg/mL fungizone, at 37 1C, in a humidified atmosphere of 5% CO 2 . Cardiomyocytes were isolated from neonate Wistar rats as previously described (Barreto-Chaves et al., 2000) .
Vector construction
The AAV Helper-Free System (Stratagene-USA), which provides AAV2 genome and packaging vectors, was modified to become compatible with the Gateway site specific recombination system and pEntr vectors (Invitrogen Life Technologies) and has been described elsewhere (Bajgelman et al., 2013) . Briefly, we constructed pAAV-dest by cloning the recombination site excised from pcDNA/V5-DEST (Invitrogen) into pAAVCMV (Stratagene) after removing the CMV promoter/enhancer sequences. To generate the pEntr vector, we used PCR to amplify the expression cassette PGTxβ-eGFP from pAdPG-eGFP (Bajgelman and Strauss, 2008) and inserted this into pEntr-2D-topo (Invitrogen). The plasmid was digested to excise GFP and to insert a new cassette encoding VEGF-Ires-GFP (VIG) which was excised from pCMV-VEGF-Ires-GFP (Becker et al., 2006; Goncalves et al., 2010) , generating pEntr-PG-VEGF-Ires-eGFP where both human VEGFA 165 and enhanced green fluorescent protein are expressed in a single transcript. Recombination with pAAV-dest yielded the AAVPG-VIG vector. A similar strategy was used to produce AAVPG-Luc (luciferase) (Bajgelman et al., 2013) . AAVCMV-LacZ was purchased from Stratagene. Cloning details can be provided upon request.
Preparation of AAV
Viral preparations were transiently produced by co-transfection of 293T cells with the viral plasmid and packaging plasmids (conferring an AAV2 capsid) from the AAV Helper-Free System (Stratagene-USA). The supernatants and cell lysates were harvested and virus was purified using the AAV Purification Kit (Cell Biolabs-USA). Titration was done by qPCR, where a standard curve was generated using the plasmid form of the AAV vector and vector titer is measured as genome copies (GC)/ml. Preps were treated with DNAse before qPCR was performed in order to assure measurement of only encapsidated genomes. The primers used for titration of AAVPG-Luc and AAVPG-VIG amplify within the polyadenylation sequence: F-PA 5 0 -ATCTCCCCCTGAACCTGAA-3 0 and R-PA 5 0 -CGCTTCGAGCAGACATGA-3 0 . Whereas AAV-LacZ, which employs a different polyadenylation sequence, was titered with primers specific for this region: lacz-F-PA 5 0 -GGCCCAACTTGTTTATTGC-3 0 and lacz-R-PA 5 0 -CCGGAGATCCAGACATGAT-3 0 .
In vitro assays: VEGF-A, luciferase and β-Gal quantitation
Primary cells were transduced with AAVPG-VIG using 100 GC/ target cell. After 24 h media was changed and the indicated amounts of doxorubicin were added to induce p53 and the cells were incubated at 37 1C for an additional 24 h. Then the supernatant was harvested to quantify the human VEGF-A secreted by the transduced cells, using an ELISA kit manufactured by R&D System Inc -USA.
Alternatively, cells were harvested and lysed in 0.1% Triton X-100, 0.1 M Tris/HCl, pH 8.0 by a freeze/thaw treatment. The lysate was then clarified by centrifugation, 5 min, 10,000 rpm. The supernatant was transferred to a fresh tube and stored at À 20 1C. For luciferase assay, 10 ml of lysate was added to 50 ml of LAR (Promega, USA), and activity was measured using a luminometer. Luc activity was normalized by total protein, measured using Bradford reagent (Bio-Rad, USA). For the β-galactosidase assay, 30 ml of lysate was added to 100 ml of ONPG solution (77 ml of 0.1 M Na 2 HPO 4 , pH7.5, 22 ml of 4 mg/ml ONPG, 1 ml of 0.1 M MgCl 2 , and 4.5 M 2-mercaptoethanol) in a 96 well plate. The reactions were allowed to proceed for 5-15 min, 37 1C, and stopped using a 1 M sodium carbonate solution. Absorbance measurements were made at 405 nm using a microtiter plate reader. Beta gal activity was normalized by total protein, measured using Bradford reagent (Bio-Rad, USA).
In vivo transduction and β-Gal assay Male Wistar rats (3 months of age) were fed with standard laboratory chow and given water ad libitum, housed in a temperaturecontrolled room (22 1C) with a dark-light cycle of 12-12 h. All experimental procedures followed institutional guidelines for care and use of laboratory animals, and the protocols were approved by the Institutional Review Board of the University of São Paulo Medical School, Brazil.
In brief, rats were anesthetized by a mixture of ketamine (90 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). After endotracheal intubation, mechanical ventilation was initiated (model 683, Harvard Apparatus) with a volume of 10 ml/kg and a respiratory rate of 90/min. Animals were injected at five points in the left ventricle with 10 8 GC of either AdCMV-LacZ or AAVCMV-LacZ virus, as indicated, in a final volume of 100 ml. The chest was closed with 4-0 nylon sutures, the pneumothorax was evacuated, and rats were extubated and allowed to recover from the anesthesia.
After four weeks, rats were anesthetized by a mixture of ketamine (90 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.), and the hearts were removed. Each heart was washed in saline, cut into three parts, from base to apex, mechanically fixed to a sheet of cork with Tissue Tec and frozen in isopentane bath and liquid nitrogen. Next, we made 7 μm cuts. The sections were stained with X-Gal solution and incubated overnight in a humidified chamber at 37 1C.
In vivo therapeutic role of AAVPG-VIG Male Wistar rats (3 months of age) were fed with standard laboratory chow and given water ad libitum, housed in a temperature-controlled room (22 1C) with a dark-light cycle of 12-12 h. All experimental procedures followed institutional guidelines for care and use of laboratory animals, and the protocols were approved by the Institutional Review Board of the University of São Paulo Medical School, Brazil.
We used the cardiac hypertrophy model induced by thoracic aorta surgical constriction (TAC). In brief, rats were anesthetized by a mixture of ketamine (90 mg/kg, i.p.) and xylazine (10 mg/kg, i. p.). After endotracheal intubation, mechanical ventilation was initiated (model 683, Harvard Apparatus) with a volume of 10 ml/kg and a respiratory rate of 90/min. The chest cavity was entered in the third intercostal space, and the thoracic aorta was isolated. We performed thoracic aorta constriction by tying the vessel with a 2-0 nylon suture ligature against an 18-gauge needle. A sham surgery was performed as a control, without aortic narrowing. Immediately after performing TAC or sham surgery, animals were injected at five points in the left ventricle with control (AAVPG-LUC) or therapeutic viruses (AAVPG-VIG). In each case, the total volume injected was 100 ml of a preparation containing 10 9 GC/ml. The chest was closed with 4-0 nylon sutures, the pneumothorax was evacuated, and rats were extubated and allowed to recover from the anesthesia.
Assessment of cardiac function by echocardiography and hemodynamics
After 12 weeks of follow-up, morpho-functional evaluation by Doppler echocardiography was performed on the anesthetized animals 5 min after intraperitoneal injection of a mixture of ketamine (90 mg/kg) and xylazine (10 mg/kg). The images were obtained with a high-resolution 15 MHz transducer able to acquire real time images in small animals (SEQUOIA 512, ACUSON Corporation, Mountain View, CA), performed by a practiced echocardiographer (R.A. Sirvente) without knowledge of the animal condition or experimental group. Echocardiagraphy was performed during a 2 min period. M-mode and bi-dimensional mode (B-mode) were used to obtain the intracavitary dimensions and septal wall thicknesses in diastole and systole. Systolic function was estimated calculating the fractional shortening (FS) according to the ratio of LV dimensions [(dLV À sLV) Â 100/dLV], with LV internal dimensions obtained by M-mode during systole and diastole in the same cardiac cycle; and by ejection fraction (EF) using the ratio of LV volumes obtained by the Simpson biplane method. For evaluation of the LV diastolic function, the isovolumic relaxation time (IVRT) was assessed by moving the pulsed Doppler volume sample slightly toward the LV outflow tract to obtain simultaneous transmitral diastolic flow and systolic aortic flow. This parameter includes the time between aortic valve closure and mitral valve opening, representing the period of isovolumic LV relaxation (Nagueh et al., 2009) . 24 h after echocardiogram examinations, hemodynamic study with direct ventricular catheterization was done as previously described. In brief, after anesthesia with the same mixture of ketamine plus xylazine, a micro-manometer (MikroTip™ 2F; Millar Instruments Inc., Houston, TX, USA) was inserted into the LV cavity through the carotid artery to measure the intraventricular pressure. Through a small right thoracotomy, a flow ultrasound probe (Transonic Systems Inc., Ithaca, NY, USA) was positioned around the ascending aorta to estimate LV ejection. Protocols were performed in closed chests and the following parameters were analyzed: LV systolic and end-diastolic pressures, rate of change of LV pressure, heart rate, cardiac output, stroke volume and stroke work. Stroke work was calculated as the product of stroke volume Â (systolic pressure À end-diastolic LV pressure). After evaluation under basal conditions, cardiac performance was tested by acquiring these parameters under different levels of hemodynamic stress. Sudden afterload increase (AS, afterload stress) was performed by a single vasoconstrictive phenylephrine intravenous injection (PHE, l-phenylephrine hydrochloride, Sigma, St. Louis, MO, USA), with doses individually adjusted (15-25 μg/kg) to produce comparable blood pressure increases of 50-70% over the baseline. After return to baseline, moderate preload stress (MPS) was induced by volume overload where 3 ml/kg of 6% dextran was injected intravenously and followed by the same afterload stress described above. After pressure had returned once again to baseline, severe preload stress (SPS) was induced (6% dextran 2 ml/kg) and followed immediately by sudden afterload stress.
Biometry, cardiac histology and morphometry
After hemodynamic study, the right lung was excised and both the wet and dry masses (drying at 80 1C for 12 h) were determined to estimate the water content (mass loss after drying as a percentage of the wet mass). The heart was excised and weighed in order to use the ventricle mass divided by the body mass as an index suggestive of ventricular hypertrophy. Thereafter, the heart was fixed in 10% buffered formalin for 24 h, embedded in paraffin, and transversely cut into 3 mm sections. Sections were mounted onto slides and stained with hematoxylin and eosin for myocyte analysis, picrossirius red for fibrosis evaluation, or periodic acid-Schiff (PAS) for capillary density quantification. A computerized image acquisition system (Leica Imaging Systems, Bannockburn, IL, USA) was used for the analyses. Histological analysis was performed blinded to the experimental group. As an estimate of myocyte hypertrophy, the average nuclear volume was determined randomly in 50 À 70 myocytes cut longitudinally for each animal, and calculated according to the following equation: nuclear volume¼π Â D Â d 2 /6 where d ¼shorter nuclear diameter and D ¼longer nuclear diameter (Gerdes et al., 1994) . Fibrosis in the remote non-infarcted LV was considered as the collagen fibers not including perivascular fibers. After digitalization, the redstained areas were quantified as the average percentage of the total area from each of 5 randomized 200 Â magnification fields per animal. Capillary density was evaluated in 6 randomized 400 Â magnification fields per animal, where the fibers were cut transversally, being expressed as the total capillary amount per area (capillaries/mm 2 ).
